Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Membranes (Basel)
2023 Jan 18;132:. doi: 10.3390/membranes13020121.
Show Gene links
Show Anatomy links
Methylene Blue Inhibits Cromakalim-Activated K+ Currents in Follicle-Enclosed Oocytes.
Isaev D
,
Yang KS
,
Petroianu G
,
Lorke DE
,
Oz M
.
???displayArticle.abstract???
The effects of methylene blue (MB) on cromakalim-induced K+ currents were investigated in follicle-enclosed Xenopus oocytes. In concentrations ranging from 3-300 μM, MB inhibited K+ currents (IC50: 22.4 μM) activated by cromakalim, which activates KATP channels. MB inhibited cromakalim-activated K+ currents in a noncompetitive and voltage-independent manner. The respective EC50 and slope values for cromakalim-activation of K+ currents were 194 ± 21 µM and 0.91 for controls, and 206 ± 24 µM and 0.87 in the presence of 30 μM MB. The inhibition of cromakalim-induced K+ currents by MB was not altered by pretreatment with the Ca2+ chelator BAPTA, which suggests that MB does not influence Ca2+-activated second messenger pathways. K+ currents mediated through a C-terminally deleted form of Kir6.2 (KirΔC26), which does not contain the sulfonylurea receptor, were still inhibited by MB, indicating direct interaction of MB with the channel-forming Kir6.2 subunit. The binding characteristics of the KATP ligand [3H]glibenclamide are not altered by MB in a concentration range between 1 μM-1 mM, as suggested by radioligand binding assay. The presence of a membrane permeable cGMP analogue (8-Br-cGMP, 100 µM) and a guanylate cyclase activator (BAY 58-2667, 3 µM) did not affect the inhibitory effects of MB, suggesting that MB does not inhibit cromakalim-activated K+ currents through guanylate cyclase. Collectively, these results suggest that MB directly inhibits cromakalim-activated K+ currents in follicular cells of Xenopus oocytes.
Figure 1. Cromakalim-induced outward currents are inhibited by MB in follicular cells of Xenopus oocytes. (A) Currents activated by 100 μM cromakalim (left), during co-administration of cromakalim and 30 μM MB following 20 min MB preincubation (middle), 20 min recovery (right). Administration times for cromakalim are shown with solid horizontal bars. Dotted lines represent continuous MB application during recordings. (B) Time course of the peak cromakalim-activated currents are shown in the absence (filled circles) and the presence of 30 µM MB (open circles). Each data point indicates the normalized means and S.E.M. of five to six experiments. The horizontal bar represents the duration of MB administration. (C) Concentration-response curve for the inhibitory effect of MB on cromakalim (100 μM)-activated currents. Data points are shown as means ± S.E.M. (n = 4–5). The curve is the best fit of the data to the logistic equation presented in the methods section. CKL: cromakalim; MB: methylene blue.
Figure 2. Inhibition of cromakalim-induced K+ currents by MB is voltage-independent and not mediated through gap junctions. (A) Current-voltage relationship of cromakalim-activated currents recorded during 1 s voltage steps applied before (filled circles) and after application of 30 μM MB (open circles). (B) Different membrane potentials did not alter percentage inhibition of cromakalim-activated K+ currents by MB. Differences among the means of current inhibitions by 30 µM MB at different holding potentials were not statistically significant (p > 0.05, ANOVA, n = 5–7). (C) Inset to Figure 2C indicates the equivalent resistive-circuit diagram. The mean values for the sum of resistances through the oocyte gap junction (Rj), follicular cell membranes (Rf) in follicle-enclosed oocytes before (gray bars) and after 20 min administration of 30 μM MB (black bars) are shown on the right side (n = 14). Membrane resistance (Ro) of enzymatically defolliculated oocytes before and after MB treatment are presented on the left (n = 16). Values of resistances were calculated from current-voltage curves recorded in the range between –50 mV and +10 mV. (D) Effect of MB (30 μM) on cromakalim (100 μM)-induced K+ currents in control and in BAPTA-pretreated oocytes. CKL: cromakalim; MB: methylene blue.
Figure 3. The effects of MB on the cromakalim dose-response curve and the specific binding of [3H]glibenclamide. (A) Concentration-response curves for cromakalim-activated currents in the absence (filled circles) and presence (open circles) of MB (30 μM). MB was administered for 20 min, and cromakalim and MB were then co-administered for 2 min. Data points represent the mean ± S.E.M. (n = 5–6; error bars not visible are smaller than the size of the symbols). Curves show the best fit of the data to the logistic equation presented in the methods section. The concentration-response curves are normalized to maximal control cromakalim response. (B) Specific binding as a function of the concentration of [3H]glibenclamide in the absence (filled circles) and presence of 30 μM MB (open circles). Data represent the means of four experimental measurements. The incubation time was 60 min at 22 °C, pH 7.5. In order to determine nonspecific binding, samples were incubated with 10 nM of unlabeled glibenclamide. (C) Increasing concentrations of MB do not alter the specific binding of [3H]glibenclamide (1 nM). Data represent the results of 4–5 experiments. Data points show means ± S.E.M. Microsomal membranes were incubated with 1 nM [3H]glibenclamide (0.3–0.5 mg/mL for 60 min) with increasing concentrations of MB in the medium. Free and bound [3H]glibenclamide were separated by filtration. MB: methylene blue.
Figure 4. Effects of MB on K+ currents mediated through the C-terminally deleted Kir6.2 channels (KirΔC26) and the effects of cGMP modulating agents on MB inhibition of cromakalim-activated K+ currents. (A) Currents from inside-out patches in response to two s-voltage-ramps from –100 to +100 mV under symmetric conditions (140 mM K+) were recorded in the absence and presence of 30 μM MB. Leak currents, recorded in the presence of 10 mM ATP, were subtracted. (B) Time-course of the effect of 30 µM MB on K+ currents mediated through the C-terminally deleted Kir6.2 channels (KirΔC26) in the absence (filled circles) and presence (open circles) of MB (30 μM), respectively. The horizontal bar represents the administration time of MB. (C) The effects of 20 min preincubation with BAY 58–2667 (3 µM) and 8-Br-cGMP (100 µM) on inhibition of cromakalim (100 μM)-activated K+ currents by MB (30 µM) in follicle-enclosed oocytes (p > 0.05, n = 5–7, Student’s t-test). MB: methylene blue; Bay 58: BAY 58–2667.
Abi-Gerges,
Methylene blue is a muscarinic antagonist in cardiac myocytes.
1997, Pubmed
Abi-Gerges,
Methylene blue is a muscarinic antagonist in cardiac myocytes.
1997,
Pubmed
Al Mansouri,
Methylene blue inhibits the function of α7-nicotinic acetylcholine receptors.
2012,
Pubmed
,
Xenbase
Arellano,
Ion channels and membrane receptors in follicle-enclosed Xenopus oocytes.
1996,
Pubmed
,
Xenbase
Ashcroft,
New windows on the mechanism of action of K(ATP) channel openers.
2000,
Pubmed
Berrocal,
Methylene blue activates the PMCA activity and cross-interacts with amyloid β-peptide, blocking Aβ-mediated PMCA inhibition.
2018,
Pubmed
Cheng,
Pressor and vasoconstrictor effects of methylene blue in endotoxaemic rats.
1998,
Pubmed
Dascal,
The use of Xenopus oocytes for the study of ion channels.
1987,
Pubmed
,
Xenbase
Edwards,
The pharmacology of ATP-sensitive potassium channels.
1993,
Pubmed
Gribble,
The antimalarial agent mefloquine inhibits ATP-sensitive K-channels.
2000,
Pubmed
,
Xenbase
Gribble,
Pharmacological modulation of K(ATP) channels.
2002,
Pubmed
Gruetter,
Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite.
1981,
Pubmed
Guillemare,
Functional receptors in Xenopus oocytes for U-37883A, a novel ATP-sensitive K+ channel blocker: comparison with rat insulinoma cells.
1994,
Pubmed
,
Xenbase
Honoré,
Hormone-regulated K+ channels in follicle-enclosed oocytes are activated by vasorelaxing K+ channel openers and blocked by antidiabetic sulfonylureas.
1991,
Pubmed
,
Xenbase
Ignarro,
Dissimilarities between methylene blue and cyanide on relaxation and cyclic GMP formation in endothelium-intact intrapulmonary artery caused by nitrogen oxide-containing vasodilators and acetylcholine.
1986,
Pubmed
Kress,
Methylene blue induces ongoing activity in rat cutaneous primary afferents and depolarization of DRG neurons via a photosensitive mechanism.
1997,
Pubmed
Küçükkilinç,
Multi-site inhibition of human plasma cholinesterase by cationic phenoxazine and phenothiazine dyes.
2007,
Pubmed
Lavigne,
Vasopressin and methylene blue: alternate therapies in vasodilatory shock.
2010,
Pubmed
Lee,
Methylene blue induces cytotoxicity in human brain tumor cells.
1995,
Pubmed
Levin,
Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery.
2004,
Pubmed
Mannhold,
KATP channel openers: structure-activity relationships and therapeutic potential.
2004,
Pubmed
Miledi,
Chloride current induced by injection of calcium into Xenopus oocytes.
1984,
Pubmed
,
Xenbase
Müller,
Chlorpromazine and related phenothiazines inhibit the ATP-sensitive K+ channel.
1991,
Pubmed
Nánási,
Effects of methylene blue and ascorbate on transmembrane potential in frog skeletal muscle.
1995,
Pubmed
Nemeth,
Effects of methylene blue on electrical behavior of myenteric neurons.
1985,
Pubmed
Nichols,
Adenosine Triphosphate-Sensitive Potassium Currents in Heart Disease and Cardioprotection.
2016,
Pubmed
Oktay,
Effect of methylene blue on blood pressure in rats.
1993,
Pubmed
Oz,
Methylene blue and Alzheimer's disease.
2009,
Pubmed
Oz,
Methylene blue inhibits function of the 5-HT transporter.
2012,
Pubmed
Oz,
Cellular and molecular actions of Methylene Blue in the nervous system.
2011,
Pubmed
Oz,
Direct noncompetitive inhibition of 5-HT(3) receptor-mediated responses by forskolin and steroids.
2002,
Pubmed
,
Xenbase
Oz,
Functional coupling of human L-type Ca2+ channels and angiotensin AT1A receptors coexpressed in xenopus laevis oocytes: involvement of the carboxyl-terminal Ca2+ sensors.
1998,
Pubmed
,
Xenbase
Oz,
Cocaine inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes.
2004,
Pubmed
,
Xenbase
Oz,
The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes.
2007,
Pubmed
,
Xenbase
Oz,
Inhibition of cromakalim-activated K+ current by ethanol in follicle-enclosed Xenopus oocytes.
2003,
Pubmed
,
Xenbase
Ozal,
Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery.
2005,
Pubmed
Quast,
Cellular pharmacology of potassium channel openers in vascular smooth muscle.
1994,
Pubmed
Ramsay,
Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.
2007,
Pubmed
Rosenblum,
ATP-sensitive potassium channels in the cerebral circulation.
2003,
Pubmed
Rubaiy,
The therapeutic agents that target ATP-sensitive potassium channels.
2016,
Pubmed
Saitow,
The photodynamic action of methylene blue on the ion channels of Paramecium causes cell damage.
1997,
Pubmed
Sakai,
Acetylcholine induces Ca-dependent K currents in rabbit endothelial cells.
1990,
Pubmed
Sakuta,
Inhibition by histamine H1 receptor antagonists of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed Xenopus oocytes.
1994,
Pubmed
,
Xenbase
Sakuta,
Inhibition by SKF 525A and quinacrine of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed Xenopus oocytes.
1994,
Pubmed
,
Xenbase
Sakuta,
Modification by cGMP of glibenclamide-sensitive K+ currents in Xenopus oocytes.
1993,
Pubmed
,
Xenbase
Sakuta,
Atrial natriuretic factor potentiates glibenclamide-sensitive K+ currents via the activation of receptor guanylate cyclase in follicle-enclosed Xenopus oocytes.
1994,
Pubmed
,
Xenbase
Sakuta,
Inactivation of glibenclamide-sensitive K+ channels in Xenopus oocytes by various calmodulin antagonists.
1992,
Pubmed
,
Xenbase
Sanders,
Effects of methylene blue on rhythmic activity and membrane potential in the canine proximal colon.
1989,
Pubmed
Starkus,
Kinetic analysis of sodium channel block by internal methylene blue in pronased crayfish giant axons.
1984,
Pubmed
Stasch,
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.
2002,
Pubmed
Stockand,
Activation by methylene blue of large Ca(2+)-activated K+ channels.
1996,
Pubmed
Thuneberg,
Methylene blue as a pharmacological probe of intestinal pacemaker activity.
1990,
Pubmed
Tinker,
ATP-Sensitive Potassium Channels and Their Physiological and Pathophysiological Roles.
2018,
Pubmed
Tretter,
Enhanced hydrogen peroxide generation accompanies the beneficial bioenergetic effects of methylene blue in isolated brain mitochondria.
2014,
Pubmed
Tucker,
Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor.
1997,
Pubmed
,
Xenbase
Wainwright,
Methylene Blue--a therapeutic dye for all seasons?
2002,
Pubmed
Yokoshiki,
ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells.
1998,
Pubmed
Zhang,
Potentiation of 5-HT3 receptor-mediated responses by protein kinase C activation.
1995,
Pubmed
,
Xenbase